Literature DB >> 17082463

Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy.

E Mercuri1, E Bertini, S Messina, A Solari, A D'Amico, C Angelozzi, R Battini, A Berardinelli, P Boffi, C Bruno, C Cini, F Colitto, M Kinali, C Minetti, T Mongini, L Morandi, G Neri, S Orcesi, M Pane, M Pelliccioni, A Pini, F D Tiziano, M Villanova, G Vita, C Brahe.   

Abstract

OBJECTIVE: To assess the efficacy of phenylbutyrate (PB) in patients with spinal muscular atrophy in a randomized, double-blind, placebo-controlled trial involving 10 Italian centers.
METHODS: One hundred seven children were assigned to receive PB (500 mg/kg/day) or matching placebo on an intermittent regimen (7 days on/7 days off) for 13 weeks. The Hammersmith functional motor scale (primary outcome measure), myometry, and forced vital capacity were assessed at baseline and at weeks 5 and 13.
RESULTS: Between January and September 2004, 107 patients aged 30 to 154 months were enrolled. PB was well tolerated, with only one child withdrawing because of adverse events. Mean improvement in functional score was 0.60 in the PB arm and 0.73 in placebo arm (p = 0.70). Changes in the secondary endpoints were also similar in the two study arms.
CONCLUSIONS: Phenylbutyrate was not effective at the regimen, schedule, and duration used in this study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082463     DOI: 10.1212/01.wnl.0000249142.82285.d6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

Review 1.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  Spinal muscular atrophy: advances in research and consensus on care of patients.

Authors:  Ching H Wang; Mitchell R Lunn
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

3.  SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR.

Authors:  Francesco Danilo Tiziano; Anna Maria Pinto; Stefania Fiori; Rosa Lomastro; Sonia Messina; Claudio Bruno; Antonella Pini; Marika Pane; Adele D'Amico; Alessandro Ghezzo; Enrico Bertini; Eugenio Mercuri; Giovanni Neri; Christina Brahe
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

4.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

Review 5.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 6.  Perspectives on clinical trials in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; John T Kissel; Thomas O Crawford; Mark B Bromberg; Gyula Acsadi; Guy D'Anjou; Kristin J Krosschell; Sandra P Reyna; Mary K Schroth; Charles B Scott; Louise R Simard
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

7.  Prospective cohort study of spinal muscular atrophy types 2 and 3.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard S Finkel; Douglas M Sproule; Peter B Kang; Maryam Oskoui; Andrei Constantinescu; Clifton L Gooch; A Reghan Foley; Michele L Yang; Rabi Tawil; Wendy K Chung; William B Martens; Jacqueline Montes; Vanessa Battista; Jessica O'Hagen; Sally Dunaway; Jean Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Mark Punyanitya; Megan J Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

Review 8.  Spinal muscular atrophy: journeying from bench to bedside.

Authors:  Tomoyuki Awano; Jeong-Ki Kim; Umrao R Monani
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 9.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

Review 10.  Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein.

Authors:  Ryan S Anderton; Bruno P Meloni; Frank L Mastaglia; Sherif Boulos
Journal:  Mol Neurobiol       Date:  2013-01-13       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.